Ozempic Twist: Clocks Run Slower?

White pills and syringes arranged on a reflective surface

A weight-loss drug just showed it can slow the biological clock inside your cells — and the numbers are hard to ignore.

Quick Take

A 32-week clinical trial found semaglutide, the active ingredient in Ozempic and Wegovy, slowed biological aging markers by up to 9% in adults with HIV.
Brain aging slowed by 5 years and cardiovascular aging by 4.3 years on specialized epigenetic clocks — even after researchers controlled for weight loss.
The study is a preprint, not yet fully peer-reviewed, and was conducted in a specific HIV patient population — so broad claims need caution.
A co-author works for the company that built the aging clocks used in the trial, raising conflict-of-interest questions worth watching.

What the Trial Actually Found

Researchers ran a double-blind, placebo-controlled trial with 84 adults who had HIV-associated lipohypertrophy — a condition where fat builds up abnormally, often around the belly. Half got once-weekly semaglutide injections for 32 weeks. Half got a placebo. Then scientists measured biological age using DNA methylation-based epigenetic clocks — tools that read chemical marks on your DNA to estimate how fast your body is aging at the cellular level.

The results across three independent aging clocks were striking. The PCGrimAge clock showed participants on semaglutide aged 3.08 fewer biological years per calendar year. The PhenoAge clock showed 4.9 fewer years. The DunedinPACE clock — which measures the pace of aging — slowed by 9%. All three results cleared the statistical significance threshold with p-values below 0.01. Critically, these effects held up even after researchers adjusted for body weight, inflammation markers, and fat distribution — meaning the slowdown was not simply a side effect of losing weight.

Brain and Heart Clocks Tell a Similar Story

Beyond the main aging clocks, researchers ran 11 organ-specific biological age tests. Brain aging slowed by 5 years. Cardiovascular aging slowed by 4.3 years. Inflammation-linked aging measures also dropped consistently. These are not trivial numbers. If they hold up in larger, broader trials, they suggest semaglutide may be doing something meaningful at the cellular level — not just shrinking waistlines.

The mechanism likely involves the drug’s powerful anti-inflammatory effects. Semaglutide reduces chronic inflammation and lowers harmful metabolic byproducts that accelerate cellular wear and tear. HIV patients already carry a heavy inflammatory burden from the virus and from decades of antiretroviral treatment. That inflamed baseline may be exactly why the drug’s anti-aging signal showed up so clearly here.

The Caveats Are Real and They Matter

Before anyone rushes to reframe Ozempic as a fountain of youth, the study’s own authors pump the brakes. This is a preprint — posted to medRxiv in July 2025 and submitted to Nature Communications, but not yet fully peer-reviewed. The authors themselves call the results preliminary. The sample size of 84 people is modest. And the HIV-specific population limits how far these findings can travel. A separate glucagon-like peptide-1 (GLP-1) drug trial in generally healthy adults showed no reduction in aging markers at all — a direct warning against overgeneralizing.

Researchers found that semaglutide, the active ingredient in Ozempic and Wegovy, slowed biological aging markers in adults with HIV, marking the first clinical evidence that the drug may influence human aging. Although the findings are encouraging, scientihttps://t.co/QP8NYXGo9X

— Michael W. Deem (@Michael_W_Deem) July 14, 2026

There are also mixed signals within the data itself. Telomere length — another biological aging marker — actually shortened slightly during the trial, even as the epigenetic clocks improved. Intrinsic Capacity, a functional measure of how well the body actually performs, showed no change at all. These contradictions do not cancel the positive findings, but they do remind us that aging is complex. No single drug has ever cleanly reversed it, and no single study should be treated as proof that one has.

A Conflict of Interest Worth Knowing

One more flag deserves attention. Varun Dwaraka, a co-author on the study, serves as director of research at True Diagnostics — the company that developed the DunedinPACE and SystemsAge epigenetic clocks used to measure results in this very trial. True Diagnostics also promoted the trial results on its own website. That is not automatically disqualifying — industry-academic partnerships are common in modern research. But it is the kind of detail that peer reviewers and independent scientists will scrutinize closely, and that readers deserve to know upfront.

What Comes Next Determines Everything

The honest answer right now is this: the findings are genuinely exciting, the methodology is more rigorous than most early anti-aging claims, and the biological plausibility is real. GLP-1 drugs like semaglutide reduce inflammation, improve metabolic function, and appear to influence cellular aging pathways in ways researchers are only beginning to map. But a 32-week trial in 84 HIV patients is a starting gun, not a finish line. Independent replication in healthy adults, longer follow-up periods, and full peer review are the next hurdles. Until those boxes are checked, semaglutide is a promising candidate — not a proven anti-aging drug.